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Abstract:
Background: Neglected tropical diseases (NTDs) affect a huge population of the world and the
majority of the victims belong to the poor community of the developing countries. Until now, the
World Health Organization (WHO) has identified 20 tropical diseases as NTDs that must be
addressed with high priority. However, many heterocyclic scaffolds have demonstrated potent
therapeutic activity against several NTDs.
Objective: There are three major objectives: (1) To discuss the causes, symptoms, and current
status of all the 20 NTDs; (2) To explore the available heterocyclic drugs, as well as their
mechanisms of action (if known), that are being used to treat NTDs; (3) To develop general
awareness on NTDs among the medicinal/health research community and beyond.
Methods: The 20 NTDs have been discussed according to their alphabetic orders along with the
possible heterocyclic remedies. The current status of treatment with an emphasis on the
heterocyclic drugs (commercially available and investigational) has been outlined. In addition, a
brief discussion of the impacts of NTDs on socio-economic conditions is included.
Results: NTDs are often difficult to diagnose and the problem is worsened by the unhealthy
hygiene, improper awareness, and inadequate healthcare in the developing countries where these
diseases primarily affect poor people. The statistics include the duration of suffering, the number
of individuals affected, and access to healthcare and medication. The mechanisms of action of
various heterocyclic drugs, if reported, have been briefly summarized.
Conclusion: Scientists and pharmaceutical corporations should allocate more resources to reveal
the in-depth mechanism of action of many heterocyclic drugs that are currently being used for
the treatment of NTDs. Analysis of current heterocyclic compounds and the development of new
medications can help in the fight to reduce/remove the devastating effects of NTDs. An opinionbased concise review has been presented. Based on the available literature, this is the first
attempt to present all the 20 NTDs and related heterocyclic compounds under the same umbrella.

Keywords: Neglected tropical diseases, NTDs, Bacterial, Viral, Heterocycles, Heterocyclic
drug, Parasite, Infection, Infestation.

1. INTRODUCTION
Neglected tropical diseases (NTDs) are responsible for the prolonged misery and
suffering of people across the world. NTDs, unfortunately, exist in those countries that are
financially backward with no appropriate healthcare available. NTDs have a devastating impact
on the health and social life of human beings. However, because these diseases are often
neglected, human suffering is perpetuated by the lack of research and development of novel
treatments. According to the WHO, there are approximately 20 different categories of diseases
that may be classified as neglected tropical diseases. Neglected tropical diseases affect over 149
countries around the world and are responsible for the loss of billions of dollars in economic
costs. The 20 diseases that are relevant to this discussion include Buruli ulcer, Chagas’ disease,
Dengue, Severe dengue and Chikungunya, Dracunculiasis (guinea-worm disease),
Echinococcosis, Foodborne trematodiases, Human African trypanosomiasis (sleeping sickness),
Leishmaniasis, Leprosy (Hansen’s disease), Lymphatic filariasis, Mycetoma, Onchocerciasis
(River blindness), Rabies, Scabies, Schistosomiasis, Soil-transmitted helminthiases, Snakebite
envenoming, Taeniasis/Cysticercosis, Trachoma and Yaws. Some of these diseases are
transmitted by carriers. The lack of proper sanitation and the subsequent proliferation of vectors
exacerbate the problem. For example, Leishmaniasis is caused by the infection of the leishmania
protozoan and is carried by the female phlebotomine sandflies. Affected people are often left
without treatment or cure. Complete cure of leishmaniasis is possible by early-stage detection
and access to appropriate sanitation and health care facilities [1].
On the other hand, ‘heterocycles’ or ‘heterocyclic compounds’ are mostly organic
compounds in which at least one cyclic (ring) framework is present that contains one or more
heteroatom(s) as ring constituent. Heteroatom signifies any non-carbon atom (except hydrogen)
and the most widely used heteroatoms, that are present in heterocycles, are nitrogen, oxygen,
sulfur, phosphorus, etc. Several heterocyclic moieties are found as important pharmacophores
(molecular scaffolds that are responsible for pharmacological activity) in drug discovery
research. Heterocycles, therefore, are an interesting and extremely important focal point in the
search for new drugs to combat neglected tropical diseases. It was reported that nine out of the
twenty-one best-selling drugs in 2013 were heterocyclic compounds [2]. This promising number
indicates that heterocycles play a highly significant role in medicinal chemistry and drug

development research. Because of the presence of heteroatom(s) as ring-constituent(s),
heterocycles are candidates for better binding with the disease-causing proteins through extended
protein-ligand interactions as compared to their carbocyclic counterparts. Therefore, if one
describes in detail and understands the mechanism of action of various heterocycles in neglected
tropical diseases, there is a greater probability of developing effective heterocyclic drugs for the
treatment of NTDs. This explanatory discussion is focused on the pharmacologically active
heterocycles and their mechanisms of action in the treatment of neglected tropical diseases.
Commercially available heterocyclic drugs that are being used for the treatment of NTDs have
been presented in Figure 1. Investigative heterocyclic molecules (mostly patented) that are under
various pre-clinical/clinical trials are shown in Figure 2. An overview of the 20 neglected
tropical diseases, their present status, and available treatments have been briefly presented in
Table 1. To the best of our knowledge, based on the available literature, this is the first
comprehensive effort to summarize the possible biological and environmental causes, current
status, various influencing factors, and socio-economic impacts of NTDs that correlate the
effectiveness of heterocyclic compounds in the treatment of 20 NTDs.
<Figure 1>
<Figure 2>
<Table 1>
Table 1. An overview of the NTDs, their current status and available treatments as defined by the
WHO.

Neglected
tropical disease
(NTD)
Buruli ulcer

Number of cases

Global impact

2015: 2046
2016: 1920
2017: 2209

Chagas’ disease

6 to 7 million

Dengue and
severe dengue

95% credible
interval indicates
284-528 million
infections per year

Dracunculiasis

Middle 80s: 3.5
million
2007: < 10,000
2012: 542
2013: 148
2014: 126
2015: 22
2016: 25
2017: 30

33 Countries
including Africa,
North and South
America, Asia and
Western Pacific
regions
Primarily in 21 Latin
American countries
Majority of Asian
and Latin American
states with global
outbreaks
(128 countries and
3.9 billion at risk)
Reduced severity
compared to ‘80s

Echinococcosis

Approximately 1
million people at
any time
200,000 infections
estimated annually

Foodborne
trematodiases

Human African
trypanosomiasis
(Sleeping
sickness)

Found on all
continents,
excluding Antarctica
East Asia and South
America have the
highest rates, 2
million life years lost
per year
3 epidemics: 1896- 36 sub-Saharan
1906, 1920, 1970- African countries
1990’s
affected, at-risk
1998: 40,000
population of 65
reported (300,000 million
total)
2009: 9878
2015: 2804
Number of cases
(actual): 20,000

Primary drug
and/or method of
treatment
Rifampicin
Clarithromycin
Streptomycin
Moxifloxacin

Ref.

Nifurtimox
Benznidazole
Vaccine
Fluid Level
Regulation

[6]

Currently no
treatment is
available

[13]

Deworming
Surgery
Albendazole
Praziquantel
Triclabendazole

[17]

Pentamidine
Suramin
Melarsoprol
Elornithine
Nifurtimox

[26]

[3]

[9]

[20]

Leishmaniasis

700,000 to
1,000,000 cases
per year

20,000 – 30,000
deaths per year.
Affects highly
impoverished people

Leprosy

2016: 108
Prevalence rate of
0.29/10,000;
16 million treated
2000: 120 million
affected people, 40
million were
disabled

Eliminated as a
public health
problem achieved in
2000.
856,000,000 people
across a total of 52
countries remain at
risk.

Lymphatic
filariasis

Mycetoma

Onchocerciasis
(River
blindness)

Rabies

6.7 billion
treatments
administered since
2000
Data is lacking
(non-notifiable
disease)
1974-2002: 40
million Africans
treated
2015: 119 million
Africans treated
2016: 132 million
Africans treated
2015: 11/13
regions prevented
disease
transmission in the
Americas.
Thousands of
deaths and cases
per year, primarily
in Africa.

Sodium
Stibogluconate
Meglumine
Antimoniate
Miltefosine
Amphotericin B
Deoxycholate
Lipid Formulations
Paromomycin
Gentamycin
Thermotherapy
(Temperature
therapy)
Dapsone
Rifampicin
Clofazimin

[30]

[34]

Albendazole
[37]
Ivermectin
Diethylcarbamazine
Citrate

Endemic disease in
Antibiotics
Africa, Asia, Europe, Antifungals
and Latin America
Only 1% of infected Ivermectin
people reside outside
of 31 African
countries. Isolated
cases in Latin
America and Yemen.

[41]

It occurs in 150
countries and
regions globally.
Present on all

[49]

Vaccine
Immunoglobins

[43]

Schistosomiasis

Soil-transmitted
helminth
infections

Snakebite
envenoming

Taeniasis
cysticercosis

Trachoma

2016: 206.4
million people
required
preventative
intervention
In 2000, according
to WHO data,
death rate is
estimated to be
200,000 annually
1.5 billion people
are currently
infected with the
disease
5.4 million receive
snakebites per
year, with close to
2.7 million of
these cases
involving
envenoming
The result of this
includes between
81,410 to 137,880
deaths and
amputation and
disability in higher
numbers.
The number of
people suffering
from
neurocysticercosis
is approximately
2.56-8.30 million.
Responsible for
visual loss in 1.9
million people.
2016: 190.2
million people at
risk
2016: 260,000
received surgery
and 85,000,000

continents excluding
Antarctica.
Incidence has been
Praziquantel
reported in 78
countries. It has been
inferred that 91.4%
of cases occur in
Africa.

[54]

Infections are
concentrated in the
regions of Africa,
the Americas, Asia,
and China.
Most of the cases
occur in Africa,
Asia, and Latin
America.

Deworming

[58]

Antivenom

[61]

Affects those in
Africa, Asia, and
Latin America and
inhibits daily life.
Loss of 2.8 million
life-years (T. solium)
41 countries have
people suffering
from the disease.
Lost productivity
approximately 2.95.3 billion USD (8
with trichiasis)

Praziquantel
Niclosamide
Albendazole
(corticosteroids and
anti-epileptics may
be used)
Azithromycin
Surgery

[65]

[68]

Yaws

received
antibiotics
8/13 endemic
countries
experienced
greater than
45,000 cases

73 countries
previously endemic
and 13 currently
confirmed endemic.

Azithromycin
Benzathine
Penicillin

[73]

2. Buruli ulcer
Buruli ulcer is a neglected tropical disease that is caused by the bacterium Mycobacterium
ulcerans. The disease is named after the Buruli district in Uganda where early cases were
detected. Although the disease is specific to the skin but in some cases, the bone may also be
affected seriously. The mechanistic actions of the frequently used drugs have not been studied in
detail. Until now, the disease has been reported from 33 countries in the world. The disease is
very toxic and eventually, total disability may result. Generally, the treatment for the disease is
given by a mixture or cocktail of antibiotics. It is very interesting to note that every single
antibiotic that is used in the fight against Buruli ulcer contains a structure that possesses a
heterocyclic moiety (Figure 1). One combination is rifampicin and streptomycin in a prescribed
amount of approximately 10 mg/kg of the bodyweight to be taken once a day for rifampicin and
15 mg/kg of the bodyweight for streptomycin. Another is the combination of rifampicin and
clarithromycin in dosages of 10 mg/ kg of the bodyweight once daily and 7.5 mg/kg of the
bodyweight twice daily, respectively. A third, unverified combination that has demonstrated
better results in isolated, non-clinical trial, is a combination of a 10 mg dose of rifampicin with
400 mg of moxifloxacin once a day. There are three primary categories of the disease (Figure 3).
The first category is characterized by a small abrasion, the second by plaques including those
that are ulcer forming and may contain swelling, and the third involving bone inflammation [3].
Thus, it seems clear that there is almost no specific and extremely effective drug for the
treatment of Buruli ulcer. It has been reported that 2-piperazin-1-yl-4H-1,3-benzothiazin-4-one
derivatives (Figure 2) exhibited better activity although extensive clinical trials are required.
Substituted derivatives of the compounds may lead to developing new viable molecules that can
be used for more effective treatment of Buruli ulcer [4].

<Figure 3>
3. Chagas’ disease
Chagas’ disease (named after the Brazilian sanitary physician Carlos Chagas, widely known as
American trypanosomiasis) is caused by a vector-borne parasite, Trypanosoma cruzi. Apart from
humans, the presence of T. cruzi has also been detected in more than 150 species of mammals
and marsupials [5]. This disease, through its impact on human health, is a significant economic
and social problem. Currently, about 6-7 million people are infected by this disease.
Unfortunately, appropriate health care development requires huge money. For example, in 2008
Columbia spent 267 million dollars to remediate the devastating impact of Chagas’ disease. The
cost of insecticide to prevent this treatment would have been a mere 5 million dollars. As
Benjamin Franklin said, “An ounce of prevention is worth a pound of cure.” The feces and urine
of the triatome bug are involved in infection. The insect bites the human on the epidermis and
expels waste products shortly afterward. The organismal waste contains parasites that the bug
has picked up, and when an individual move to brush away the bug or scratches the wound, these
wastes are agitated into the wound; this allows entry into the circulatory system. Waste products
may be incorporated into the eyes and mouth and regions where the epidermis has been broken.
The disease also may be transmitted by vertical transmission, organ transplant operations, and
the ingestion of food that is laced with contaminants. [6].
When discussing Chagas’ disease, as of now, there are only two main drugs used in clinical care,
although neither of these is particularly potent. These two drugs are nifurtimox and benznidazole
(Figure 1). Both drugs exhibit significant toxicity and produce the best results for those who
exhibit acute symptoms of the disease. In patients who have been immunocompromised, the
drugs exhibit a reduced therapeutic efficacy. The chemical basis of both medications’ efficacy
involves the process of reduction of the nitro group. For nifurtimox, the reaction is involved in
producing a negatively charged nitro containing moiety, which is further responsible for the
synthesis of reactive oxygen that imparts pharmacological activity. Benznidazole reacts in a
fashion such that many stable, regularly occurring covalent bonds in macromolecules are altered.
More specifically, the mode of action involves the formation of nitro anion radicals by
nitroreductase II, which subsequently induces the activity of redox cycling. Radicals, by their
nature, allow single electron transfer reactions to take place leading to the ultimate production of

superoxide. Also, DNA mutilation is encouraged by reduction reactions. Here a pair of electrons
is used to reduce nitro to nitroso groups. This process undergoes catalysis by nitroreductase I. In
a biological system, many structures are susceptible to oxidation or reduction; this explains both
the effectivity and the side effects of these medications. The balance between the two is
determined by specificity. It is notable that both the drugs involve the heterocycle moiety. Some
other molecules are currently under the developmental stage to remediate the side effects and
increase the potency of treatment. The heterocyclic drugs posaconazole, and ketoconazoleterbinafine combination (Figure 1) are currently in the clinical trial phase [7]. Recently, 2ferrocenyl benzimidazole [2-(Ferrocyn-2-yl)-1H-benzimidazole] has been reported [8] that
demonstrated about 2.5 times better activity than the positive control (nifurtimox) on INC-5
Trypanosoma cruzi strain. The compound was synthesized following a one-step microwaveassisted green procedure. The structure of 2-(Ferrocyn-2-yl)-1H-benzimidazole is shown in
Figure 2.
4. Dengue/Severe Dengue and Chikungunya
Both dengue and chikungunya are classified as neglected tropical diseases.
Unfortunately, approximately half of the world’s population is at risk from these two neglected
tropical diseases. Like Chagas’ disease, dengue is transmitted through a vector. The vector is
specifically harbored by female mosquitoes of the Aedes genus, including Aedes aegypti and
Aedes albopictus. Aedes aegypti is a common vector of both dengue and chikungunya viruses.
Many Asian and Latin American regions have been affected and many new patients are infected
and die every year due to these two diseases. When referring to dengue, four diseases actually
are being considered. Each strain of the virus is labeled as DEN-#, where # represents the
numbers 1-4. Somewhat beneficially, those who are infected by a particular DEN variant are
generally granted immunity. However, this does not preclude the infection of other DEN
derivatives. Due to the lack of a consensus of dengue infection prevalence, some estimates vary
from 390 million new infections a year to a staggering 3.9 billion people who are assumed to be
at risk for infection. One of the compounding factors is that an infected female mosquito is able
to carry the virus indefinitely. Quite ironically, the infected human patient becomes the
mechanism for the further propagation and subsequent infection of more carriers. Treatment of
dengue is very non-specific and presents a large challenge.Besides, 75.38% of those infected

with dengue are asymptomatic carriers of the viral infection. Although, medical intervention can
have a significant impact on mortality rate, mostly by regulation of fluid levels, a medication for
dengue fever could have a great impact. Regulation by medication or by vector control would be
particularly useful as the virus originally came from cattle, and thus its propagation may not be
completely halted. The first dengue vaccine was developed and introduced by late 2016 and is
now being recommended to individuals older than 9 up to the age of 45 years [9].
There is hope, however, especially in the synthesis and use of heterocyclic drugs.
Substituted and unsubstituted phenyl-heteroaryl-aryl compounds have been shown to exhibit
antiviral activity against strains of the dengue virus. However, the activity of the compounds
seems non-specific. In that case, the compounds may be effective against a multitude of viruses
that generate pathological symptoms in humans [10]. Four benzimidazolium derived nitrilefunctionalized mononuclear-Ag(I)-N-heterocyclic carbene and binuclear-Ag(I)-N-heterocyclic
carbene (Ag(I)-NHC) hexafluorophosphate (Figure 2) complexes were shown to demonstrate in
vitro antibacterial activity. The intercalating action of nuclease on DNA was demonstrated as the
mechanism of action and thus larvicidal activity was demonstrated against Aedes albopictus. The
toxicity to the insect was increased in a dose-dependent manner, a useful property for a drug-like
molecule [11].
5. Dracunculiasis
Dracunculiasis (also known as Guinea-worm disease) is a parasitic disease that is
currently under control. It is wonderful to note that since the 1980’s the number of cases has
dropped from approximately 3.5 million cases to only 30 cases in the year 2017. However,
occurrences of dracunculiasis have been recorded even in 2018 in Chad, South Sudan and
Angola [12]. A schematic diagram of dracunculiasis is presented in Figure 4.
The mechanism behind this decrease can be attributed to the concerted efforts of the WHO and
the United States CDC (Centers for Disease Control and Prevention) in developing a campaign
for eliminating dracunculiasis. Ongoing monitoring and certification of countries after the
improvement of water supplies has ensured lasting results. The disease is transmitted through
contaminated water supply sources that contain water fleas that are infected with guinea worm
larvae. The guinea worm is taxonomically identified as Dracunculus medinensis and the disease

process generally is not fatal but results in annoyance and discomfort for many days. Following
initial infection, approximately one year later, a worm is expelled from a blister formed on the
lower body. The worm then releases larvae into the water source that is almost always used to
bathe and douse the irritable wound. If the water is not sequestered as biohazardous waste, the
cycle begins again. The initial ingestion of water fleas infected with guinea worm larvae is what
allows the transmission of the actual disease-causing parasite. The water fleas are killed and
lysed in the stomach, and from the remains of the water flea, the larvae of the guinea worm are
released. The worms penetrate the gut wall and move throughout the body and finally, a female
worm becomes fertile and migrates to the lower limbs and is released. The subsequent release of
offspring into the water allows further reincorporation of the worm into more water fleas when
water fleas prey on the guinea worm larvae. This leads to another infectious cycle. Therefore, the
availability of safe drinking water and proper sanitation are important to prevent the transmission
of dracunculiasis. Unfortunately, no treatment is currently available for this disease [13].
<Figure 4>

An interesting development for this disease, especially because the incidence is so low, is
the development of new low molecular weight molecules that can be used generally in the
treatment of those pathological infections caused by parasites. Natural heterocyclic chamigrane
endoperoxide, merulin A derivatives, obtained in Endophytic fungi, demonstrated positive
laboratory effectiveness against parasitic infections [14]. It is important to note that merulin A is
under trial for the treatment of another NTD African sleeping sickness. Therefore, it seems that
although no specific work is being done to make a medication for dracunculiasis parasitic
disease, there are continued efforts for other neglected tropical diseases which in turn may confer
positive benefits in the treatment process for related diseases.
6. Echinococcosis
Echinococcosis is one of the most severe parasitic tropical diseases (Figure 5). The
general classification of echinococcosis is multifactorial in that four unique diseases fall under
this category. These diseases are cystic echinococcosis, alveolar echinococcosis, polycystic
echinococcosis and finally unicystic echinococcosis. Cystic echinococcosis and alveolar

echinococcosis are the most troublesome due to their abundance. From the parasitic perspective,
there are two distinctive hosts: intermediate and definite. The intermediate hosts are those
animals that consume contaminated food or water that is laced with the eggs of the parasite. The
parasite then uses the intermediate host to develop and proliferate in the living tissue. Tertiary
consumers ingest the infected tissue of the lower trophic level organisms and are the definite
host. The developed tapeworm is stored in the intestinal organs of the definite host. Humans can
be considered as an intermediate host, although humans are not directly involved in the cycling
of the parasite. Cystic echinococcosis is caused by Echinococcosis granulosus and alveolar
echinococcosis is caused by Echinococcosis multilocularis. Even though a variety of hosts may
be implicated, cystic echinococcosis preferentially utilizes the dog-sheep-dog cycle of infection
and alveolar echinococcosis uses small carnivore/mammalian like domesticated dogs and cats.
Symptoms for cystic echinococcosis include the formation of hydatid cysts in the lungs and liver
and can lead to nausea, cough, vomiting, pain in the chest, and shortness of breath. Weight loss
and weakness also can result. Incubation may last multiple years and may not be accompanied by
any symptoms. For alveolar echinococcosis the growth of a tumor-like mass in the liver can be
accompanied by subsequent metastases to adjacent tissues. This spread of the disease will allow
the parasite to infect the rest of the body and can lead to fatality as well as weight loss, pain in
the abdomen and eventually hepatic failure [15,16].
The treatment of these diseases is just as complicated as their method of infection. The treatment
of cystic echinococcosis involves either a technique where a puncture and subsequent aspiration
technique is employed, surgery, drug administration or allowing a natural progression and
subsequent expulsion of the disease. For alveolar echinococcosis, an intensive surgery, related in
many ways to tumor removal, must proceed along with drug utilization to prevent infection. It is
important to note that currently a heterocyclic benzimidazole drug, albendazole (brand name:
Albenza; Figure 1), is used for this purpose (anti-parasitic activity). However, random surgery
especially after metastasis may afford temporary pain relief but does not provide a permanent
solution. Thus, treatment is primarily focused on the removal of worms from hosts, using
vaccines for hosts and removing diseased animals from a population [17].
<Figure 5>

Apart from albendazole, another heterocyclic drug mebendazole (brand name: Emverm),
containing a benzimidazole core, is frequently used for the treatment of echinococcosis. Both
albendazole and mebendazole showed promising results by reducing infection in the treatment of
echinococcosis. The common pharmacophore in these heterocyclic compounds is the guanidinefused benzimidazole. Notably, some other neglected tropical diseases such as Human African
trypanosomiasis, Buruli ulcer, Chagas’ disease, Onchocerciasis, Leishmaniasis, Taeniasis
Cysticercosis, and Lymphatic Filariasis are responsive to guanidine-containing heterocyclic
derivatives. The guanidine-containing scaffold seems to allow antiprotozoal and antiparasitic
action to occur [18]. In 2017, it has been reported that a few amino alcohol-containing
heterocycles might be used to treat the disease. It was determined that the invention will facilitate
the discovery of lead compounds that can treat echinococcosis and will hopefully usher in a
targeted drug development process [19].
7. Foodborne trematodiases
As the name suggests, the disease is transmitted by eating contaminated foods that
contain trematode worms. These foods can come from a variety of sources. Of particular
importance is unprocessed/undercooked or raw food including vegetables, fish and other and
crustaceans that nurture the tiny larvae of the worms. Interestingly the parasites are unable to be
transmitted directly to human hosts and must pass through multiple intermediary hosts before the
transmission to a human may occur. The first host must always be a freshwater snail. The second
host may involve either a fish which lives in non-saline environments or various crustacean
species. Additionally, a lack of a second intermediate host is possible. The terminal host must be
a mammalian species. Therefore, there are two mechanisms of infection: Eating an infected host
(fish, crustaceans, etc.), or consuming larvae infested vegetables found in aquatic environments.
Depending on the specific infectious species and the organ from which the adult worms are
found, effects are organ and patient-specific. Generally, the disease leads to chronic conditions
and is unnoticed until much later after infection. In the cases of both clonorchiasis (infectious
parasite: Clonorchis sinensis; carrier: fish) and opisthorchiasis (infectious parasite: Opisthorchis
viverrini; carrier: fish), the formation of bile duct cancer and severe inflammation of the various
bile ducts may occur due to presence of the worms. Fascioliasis (infectious parasite: Fasciola
hepatica/gigantica; carrier: aquatic vegetables) is characteristically associated with symptoms

occurring in the larger bile ducts in addition to the gallbladder where aching, anemia,
inflammation as well as jaundice are common symptoms. Regarding paragonimiasis (infectious
parasite: Paragonimus spp.; carrier: crustaceans), the symptoms that occur are respiratory,
including cough with bloody regurgitation, pain in the chest, trouble respiring and a febrile state.
Therefore, depending on the particular parasite and the part of the body (organ) that hosts the
parasite, the symptoms are different [20].
Effective and specific medication has been developed for the treatment of foodborne
trematodiases. For clonorchiasis and opisthorchiasis, a tricyclic azaheterocycle, praziquantel
(Figure 1) should be given in a dosage of 25 mg/kg of the bodyweight 3 times per day for 3 days.
For preventative purposes, 40 mg/kg of the bodyweight should be delivered once. For
fascioliasis, a benzimidazole derivative, triclabendazole (Figure 1) is generally recommended in
the manner of 10 mg/kg of body weight once and if ineffective, the dose may be repeated. For
preventative measures, 10 mg/kg of the bodyweight may be given in a single administration.
Alternatively, in the case of infection with paragonimiasis, praziquantel may be given in the
amount of 25 mg/kg of the bodyweight for 3 times a day for 3 consecutive days. For prevention,
triclabendazole is prescribed once in the amount of 20 mg /kg of the body weight [20]. Figure 6
represents the key features of foodborne trematodiases.
<Figure 6>
Notably, artemisinin derivatives were also shown to be inhibitors of trematode worms
and demonstrated the potential of becoming good alternative drugs for the treatment of this
disease. Artemisinin (Figure 1) derivatives and synthetic trioxolanes demonstrated significant in
vivo efficacy under laboratory conditions. Once again, derivatives of both compounds are
heterocyclic in nature. Interestingly, artemisinin derived drugs such as artesunate and artemether
have already been proved as highly safe and effective drugs in malaria treatment, so it is
somewhat logical to think that a positive benefit may be had with artemisinin derivatives in the
treatment of foodborne trematodiases [21]. Heterocyclic drug development for this disease seems
promising.
8. Human African trypanosomiasis (Sleeping sickness)

Human African trypanosomiasis, also known as sleeping sickness, is indigenous to thirtysix sub-Saharan countries. The vector-borne disease is transmitted by the tsetse fly. The parasite
of this disease belongs to the genus Trypanosoma. Agricultural communities seem to exhibit a
particularly high incidence of the disease. This can be logically attributed to the greater presence
of the vector. There are two distinct forms of the disease: Trypanosoma brucei gambiense, which
causes more than 98% of trypanosomiasis sleeping sickness cases and a less common form of the
disease caused by Trypanosoma brucei rhodesiense, responsible for the remaining 2% of all
infections, endemic to Uganda. Unfortunately, the disease may result in asymptomatic conditions
for multiple years and when symptoms do manifest, the nervous system is often already
detrimentally affected. It is interesting to note that Chagas’ disease which is also known as
American trypanosomiasis, is caused by another Trypanosoma species called Trypanosoma
cruzi. American trypanosomiasis is considered a different disease than African trypanosomiasis
because of differences like transmitting species, symptoms, classification, and methods of
treatment. [22]. In human African trypanosomiasis (HAT) the routes of infection include vertical
transmission, insect transmission, contamination by unsterile needles, and transmission because
of sexual contact. There are two main phases of infection. In phase one, the parasite proliferates
in the lymphatic and circulatory system and results in a febrile condition, discomfort, and
itching. In the following phase, parasites cross the blood-brain barrier, exposing the brain: thus,
the central nervous system experiences devastating effects from the parasitic infection. Profound
psychological pathology such as confusion and disruption of sleep cycle regulation (from which
the name of the disease is derived) is observed. Without treatment, the disease is often fatal [23].
Five different drugs are currently used for treatment; treatment is often difficult and complex,
especially if the central nervous system is implicated. Treatment can persist for a period of up to
24 months and is difficult to administer. Treatment options are defined by the two major stages
of infection. During stage one infection, pentamidine is used due to the relatively low risk of
adverse effects. Suramin can alternately be administered despite causing allergic reactions and
urinary tract issues. Both heterocyclic and non-heterocyclic drugs are used for this treatment. In
the second stage of infection, a triazolyl dithiarsolan derivative (melarsoprol) is administered as a
remedy for both disease forms. However, the infection is resistant to treatment by this drug in
many portions of Africa and contains arsenic and therefore may result in toxicity. The drug is
used as a primary remedy for rhodesiense infection and in the follow-up treatment of gambiense

infection. Eflornithine is less toxic than melarsoprol, however, is only effective against the
gambiense infection type. This drug is also non-heterocyclic drug. Combination therapy of
eflornithine along with a furan derivative, nifurtimox, was approved by the FDA (Food and Drug
Administration) in 2009. This combination therapy has proven as an effective treatment for the
second stage infection against the gambiense form of the disease, although the combination has
not been adequately tested against the rhodesiense variant [24-26]. The structures of the two
heterocyclic drugs, melarsoprol and nifurtimox, are shown in Figure 1. Here it is important to
mention that although nifurtimox is a registered drug for American trypanosomiasis, it is not
permissible to use as a primary medication itself in the treatment of human African
trypanosomiasis although the combination therapy of nifurtimox with eflornithine is an accepted
strategy for the first-line treatment of human African trypanosomiasis.
There are other heterocyclic antiprotozoal agents that showed potential activity against
the disease. Quinolone derivatives, specifically, 4-quinolones containing a cyclic or acyclic
amine at position 7 have been reported as potent in vitro inhibitors of parasitic activity. The
compounds showed selectivity, did not significantly affect macrophages and did not harm
normal cells that could be potentially disturbed by treatment with other drugs [27]. In a relatively
recent finding, it was demonstrated that gold-containing heterocyclic compounds demonstrated
excellent activity against Trypanosoma brucei parasites. These complexes were gold (1) Nheterocyclic carbene derivates. The complex was found to achieve its therapeutic effect in two
unique ways. Complete removal of the flagella used in movement and total degradation of the
infecting species’ basic cytoskeletal structure was responsible for the biological activity [28] of
the hit gold (1) N-heterocyclic carbene derivate. This preliminary study thus demonstrates a
promising future for this organometallic/heterocyclic hybrid. Currently, an imidazole derivative
(fexinidazole) has successfully completed clinical trials (phase II/III) for the gambiense form of
HAT but clinical trials for the other form (rhodesiense) of HAT has not yet been completed. It is
extremely interesting to note that another new heterocyclic drug candidate, acoziborole (an
oxaborole derivative) has recently demonstrated significant therapeutic activity in phase I and II
clinical trials against both forms of HAT (gambiense and rhodesiense). Acoziborole is currently
undergoing phase III clinical trials. This medication is expected to be orally deliverable as a
single dose. If this expectation comes to fruition, the treatment of HAT, for both forms, will be

very simple and economical [25]. The structure of fexinidazole and acoziborole are shown in
Figure 1.
9. Leishmaniasis
Leishmaniasis is not a single disease, but rather a group of health disorders
(Leishmaniases), caused by protozoan infection by one of more than 20 unique species of the
genus Leishmaniasis. To make matters worse it is non-selectively transported by over 90 species
of tiny (only 2-3 mm long) infected female sandflies [29]. There are three major forms of
leishmaniasis disease that include visceral leishmaniasis (also called kala-azar), cutaneous
leishmaniasis, and mucocutaneous leishmaniasis. The visceral form is a deadly disease and
causes death in most of the patients who are not treated systematically. Symptoms include a
febrile condition, liver and spleen size enlargement (swelling), and anemic conditions. Cutaneous
leishmaniasis is the most frequently encountered form and causes lesions in the skin such as
ulceration. Close to one million cases occur every year. The mucocutaneous form greatly affects
the mucous membranes, specifically those present in the throat, mouth and nasal cavities [30].
<Figure 7>
Treatment options are widely varied. A pentavalent (Sb+5 ) antimonial (sodium
stibogluconate, Figure 1) has been used as the first-line medication for many years. It is a good
heterocyclic drug that is frequently used to treat all three types of leishmaniasis. Apart from that
a few non-heterocyclic drugs like meglumine antimoniate, miltefosine, and paramycin, are also
used in certain cases where resistance may occur. The intravenous (IV) dose of sodium
stibogluconate may vary from 20 mg/kg of the bodyweight to an upper limit of 50 mg/kg of the
bodyweight. An unsaturated lactone (amphotericin B, Figure 1) deoxycholate is a heterocyclic
drug with a macrolactone core that may be administered to affected patients at a concentration of
0.75-1 mg/kg of the bodyweightonce in a day for 15 to 20 days. The use of lipid formulations of
amphotericin B (liposomal amphoterin B) is also very common. Paromomycin, an amino sugar
heterocyclic drug, has also been shown to be effective and is administered in a dose of 15-20
mg/kg of the bodyweight for 3 weeks to treat visceral leishmaniasis. Certain combinations of the
drugs mentioned above were shown to be beneficial in some cases.

For the cutaneous form, paromomycin (Figure 1) alone and in combination with
gentamicin has demonstrated good results. Both drugs are heterocyclic (Figure 1). There are two
oxane (tetrahydrofuran) and one oxolane (tetrahydropyran) moieties present in paromomycin
while gentamicin contains two oxolane subunits. The Pentavalent antimonial, discussed
previously, may also be administered. Temperature therapy, including extremes of temperature
(hot and cold), applied locally may produce a beneficial effect.
For the mucosal form, pentavalent antimonial may be delivered in a dosage of 20 mg/kg
of the body weight once in a day for 30 days. Liposomal amphotericin B deoxycholate may also
be given. Amphotericin B should be given 20-45 times in a disease cycle at a concentration of
0.7-1 mg/kg of the body weight in each time. Pentamidine and miltefosine are non-heterocyclic
drugs that also may be administered. A combination of antimonials with the xanthine derivative
pentoxifylline (Figure 1) can also yield good results for a patient [31].
The research and development of heterocyclic N-oxide containing compounds seem to
hold promise for the future of heterocyclic drug development. This molecular pharmacophore
may demonstrate general positive effects against other diseases including Chagas’ disease,
tuberculosis, and malaria. The most interesting and potentially beneficial compounds were found
to be quinoxaline 1,4-di-N-oxide, indolone N-oxide, furoxan, benzofuroxan, and benzimidazole
N-oxide [32]. Recently, a benzimidazole-based compound, 2-(phenanthren-9-yl)-1Hbenzimidazole (Figure 2) demonstrated comparable pharmacological activity (in vitro) with the
positive control amphotericin B [18].
10. Leprosy
Leprosy is a chronic bacterial disease caused by the bacterium Mycobacterium leprae.
Leprosy is also called ‘Hansen’s disease’ in the namesake of Dr. Gerhard Hansen who
discovered the bacterium M. leprae in 1873. The development of pathology and symptoms
occurs over a span of time ranging from 1 year up to 20 years. This is due to the slow
proliferation rate of these bacteria. The infection results in the degradation of the limbs, skin,
eyes, and nerve tissue [33]. The disease has prevailed since ancient times, however, appropriate
monitoring by WHO and the introduction of multiple effective drugs has been particularly useful
in combatting leprosy. Figure 8 summarizes a dramatic improvement in the treatment of leprosy.

<Figure 8>

Dapsone was the first drug (non-heterocyclic) that was introduced for the treatment of
leprosy. Unfortunately, patients began to develop resistance to this drug. Therefore, the WHO
introduced multi-drug therapy (MDT) that included mainly two heterocyclic drugs: rifampicin
and clofazimine (Figure 1). The core of rifampicin is a macrolactam unit that is attached with a
tetrahydrofuran and a piperazine subunit. Clofazimine contains a phenazine heterocyclic moiety
in its core. Dapsone is a tertiary component of this MDT. This MDT has been demonstrating
excellent effectiveness for the treatment of leprosy worldwide. Over 16 million patients have
been cured of the disease in the last two decades [34]. The use of an amide, derived from a cyclic
6- or 7-membered amine, as a potentiator is currently being studied. The mechanism of
activation is believed to proceed through the monooxygenase EthA enzyme pathway [35].
Currently, this MDT is available around the world (by courtesy: WHO) free of charge and will
be available until 2020. Presently, around 250,000 people are infected by the bacterium M.
leprae, mostly those from less developed countries. Accordingly, an extension of free MDT after
2020 (Figure 8) is highly required and a justified request in line with the principle of the ‘one
world’ concept. Previously, leprosy was thought to be highly contagious and the general public
was highly fearful of this disease. Isolation of the patient and discrimination was very common.
This stigma is being weakened by continuous education and easy access to this MDT. Leprosy is
completely treatable if treated in a timely manner [36].
11. Lymphatic filariasis
Lymphatic filariasis, known commonly as elephantiasis, targets the lymphatic system and
can lead to an exponential increase in the size of specific body parts. This disease puts 856
million people at risk globally, and 36 million currently suffer from chronic symptoms. The
infection is caused by microscopic, thread-like worms (parasites) that are carried by mosquitoes.
The infection is caused by three parasites classified as nematodes. These include in order of
prevalence, Wucheria bancrofti, Brugia malayi and Brugia timori. The worms produce
pathology by their sustained residence in the lymphatic system during their lifespan of 6-8 years.
The number of larvae produced can range in the millions. The infected individual then serves as
a repository for the uptake of larvae by a mosquito. The incorporated larvae then mature within

the mosquito and the larvae may be deposited on the skin near the site where a mosquito bite is
made. The larvae then enter the body and find a suitable location to mature and the cycle is
repeated. A variety of mosquito genera including the Culex, Anopheles, and Aedes genus have
been found to be carriers of the disease. Tissue size growth (lymphoedema), epidermis and tissue
level thickening, elephantiasis and hydrocele are all symptoms of the disease. Incidences of
inflammation due to the immune response and/or bacterial infection as a result of lowered
immunity are also encountered. The disease is often very embarrassing and disrupts the social
lives of the affected individuals. Figure 9 summarizes the worldwide impact of the disease [37].
<Figure 9>

According to WHO recommendation, mass drug administration (MDA) is being
introduced which involves the annual administration of preventive chemotherapy to the
population determined to be at risk of obtaining lymphatic filariasis. Although MDA is not
entirely able to kill the adult parasites in a patient, it can effectively prevent the spread of
microfilariae from a patient’s bloodstream to a healthy person’s bloodstream through
mosquitoes. Later, the WHO modified its recommendation to suggest a treatment that could
remove the majority of microfilariae from a patient’s bloodstream in a few weeks. Interestingly,
the current recommendation includes the administration of three heterocyclic drugs: albendazole,
ivermectin, and diethylcarbamazine citrate (Figure 1). This triple drug administration involves
the administration of 400 mg of albendazole (benzimidazole-based drug) in a single dose
combined with ivermectin in a dose of 150-200 mcg/kg of the bodyweight, and
diethylcarbamazine citrate (DEC, a piperazine analog) in a dose of 6 mg/kg of the patient’s
bodyweight [38]. The treatment has been profoundly successful with an estimated savings of 24
billion dollars that would have been forfeited due to productivity loss. An interesting
development has been recently reported which involves the introduction of thiazolidine
containing compounds in the treatment of lymphatic filarial parasites. In the study being
referenced, the in vitro activity of the thiazolidine containing compounds were tested against
Brugia malayi. The scaffold demonstrated a beneficial effect and a good therapeutic index. Thus,
these molecules might have the potential for the future treatment of this disease [39].
12. Mycetoma, Chromoblastomycosis and other deep mycoses

Mycetoma is a disease that infects the subcutaneous tissue. This includes skin, bone, and
muscle. Multiple microorganism species (bacterial and/or fungal) may result in infection,
however, the infection is caused by either a bacterial or fungal organism. Generally, direct
puncture of the tissue by a contaminated object through a minor trauma or penetration results in
infection. Due to the lack of proper footwear in many countries, this chronic disease occurs
primarily in the foot, but other parts of the body can be affected. Although barefoot rural
populations in endemic areas are mostly affected, the risk of infection in these areas is
widespread. The disease has recently (Figure 10) been recognized as an NTD but it is still under
the category of ‘not notifiable’ which means reporting of the disease is not required by law.
Accordingly, data related to mortality, morbidity, and global burden are not known.
Consequently, no recommended monitoring and treatment procedures exist. The disease most
likely cannot be transmitted from human to human. The symptoms include damage to the
subcutaneous tissue. The disease is often characterized by the formation of painless masses
below the cutaneous layer along with sinuses that secrete and discharge the infecting species.
The slow development of symptoms often results in amputation and secondary bacterial and/or
fungal infection. Secondary infection can lead to sepsis in severe cases. In contrast to mycetoma,
the reason for chromoblastomycosis has been linked to fungal infection. Chromoblastomycosis is
a similar type of chronic NTD that affects the skin including cutaneous and other tissues by
causing polymorphic tumoral or nodular lesions. Among other fungal species, three particular
species viz. Fonsecaea pedrosoi, Phialophora verrucose and Cladophialophora carrionii, are
responsible for chromoblastomycosis infection [40].
<Figure 10>
As stated earlier, mycetoma, chromoblastomycosis, and other deep mycoses are badly
neglected diseases and currently, no systematic treatments are available. Based on the nature of
the infection, antibiotics and/or antifungal drugs are administered for mycetoma whereas
antifungal treatment is required for chromoblastomycosis. Due to the lack of a universal
treatment policy, various antibiotics and/or antifungal drugs (mostly heterocyclic) are used in
different parts of the world. Treatment options are poor and involve the use of a cocktail of
antibiotics and antifungal medications. Surgical operation is required in many cases. The
treatment is costly, inaccessible and ineffective in many incidences [41]. Recently, a new series

of triazole containing pyrimidine derivatives have been developed that claims to be effective
against the fungal infections of mycetoma [42]. A general structure of the compound is shown in
Figure 2.
13. Onchocerciasis
Onchocerciasis is commonly known as river blindness; this disease is propagated by a
parasitic vector. After trachoma, onchocerciasis is the second leading cause, due to parasitic
infection, of blindness worldwide. The specific vector is female blackflies belonging to the genus
Simulium. These blackflies commonly breed near pools of moving water. Thus, this infection has
a high incidence of occurrence near water sources such as streams and rivers. Pathology is
caused by the movement of mature worms, termed filarial worms, to different portions of the
eyes and epidermis. The specific species of worm that causes the disease is Onchocerca volvulus.
An infected human may also serve as a reservoir for the further propagation of the worm once a
female blackfly ingests microfilariae from an infected human when taking a blood meal. The
larvae develop to some extent in the blackfly, and the female blackfly becomes a carrier of the
disease. The dead worms in the body produce a significant inflammatory response and can be
responsible for severe bouts of itching. Progressive vision loss including the formation of eye
lesions; partial to complete blindness may occur. Raised areas of the skin are usually indicative
of the presence of adult worms. About 99% of patients live in Africa. Out of 20.9 million cases,
14.6 million cases resulted in skin disease and 1.15 million cases resulted in visual impairment
[43-45].
The current method of treatment is the administration of the heterocyclic spiro-macrolide
drug ivermectin (Figure 1) until the infection is cleared. The drug may need to be administered
every six months for a duration spanning 10-15 years. The drug has shown great success in
Africa where the majority of cases occur [43,44]. It has been reported that pyrazinyl and
pyridinyl derivatives could successfully inhibit the inflammatory response and could be
developed as useful drugs for treating symptoms of this disease [46]. Another recent report has
shown that fused heterocyclic thiazole-benzimidazole-piperazinyl-thiadiazolyl hybrids and the
corresponding Mannich bases synthesized therefrom were shown to possess potent filaricidal
activity. The pharmacological activity of these compounds was better than that of the positive

control thiabendazole. The report is interesting as both the Mannich base analog and final
product are heterocyclic molecules and showed potent filaricidal activity [47].
14. Rabies
Rabies, a commonly known zoonotic disease, causes approximately 59,000 deaths
annually around the world and about half of the cases are attributed to children or young adults
under the age of 15. The prevalence of rabies is not to be understated as its distribution includes
over 150 countries. The disease is viral, caused by the transmission of rabies virus of the genus
Lyssavirus (family: Rhabdoviridae) to the human body. Primary transmission occurs through
dogs in 99% of cases. The immediate cleansing of a wound sustained in an incidence with an
animal infected with rabies is critical and affects prognosis. Vaccination of dogs serves as a
promising treatment for eradication of this disease because of their ubiquity in many cultures and
overwhelmingly singular responsibility for causing the disease. The preemptive vaccination of
susceptible human populations is also crucial. Initial symptoms include local burning sensations
and discomfort near the site of contact. Subsequent neurological effects occur due to
inflammation of the brain and spinal cord (paralytic). This inflammation can be fatal. Two
distinct variants of the disease exist. Furious rabies results in specific symptoms such as the
phobia of moving air and water as well as a hyperactive state. Death often follows in a few days
resulting from cardiac and respiratory system failure. The second form, paralytic rabies,
generally results in the paralysis of muscles in a manner that can be described as migratory from
the initial infection site. A comatose state is induced, and death follows. Paralytic rabies is
responsible for approximately 80% of rabies cases. Notably, in the Americas, dog transmission is
not as ubiquitous, and rabies is more commonly transferred through bat bites. Death from
ingestion of tainted animal tissue meat, human transmission and rodent to human transmission
are undocumented. Transfer of the disease from other carnivores is extremely rare. Rabies is
treated by either preventive vaccination of dogs and humans, or immediate administration of
rabies immunoglobin after a rabid animal encounter has occurred. The immunoglobin treatment
is followed by the administration of an antiviral like ribavirin (Figure 1). Ribavirin is a
ribofuranosyl triazole derivative that is frequently recommended to combat rabies virus.
Unfortunately, the cost of treatment in countries such as Asia and Africa can be more than 20
times the average daily income earned [48,49].

Recently, a series of pyrazolo-fused pyridine molecules has been demonstrated to possess
antiviral activity for a panel of viruses, including rabies. The general structure of the compound
[50] is presented in Figure 2. Also, heterocyclic 3-Substituted 1,3,4-oxadiazole and thiadiazoles
have been found to exhibit antiviral activity against rabies. The mechanism of action includes the
downregulation of a cell death pathway and/or of suppressing an immunosuppression signaling
pathway. Therefore, the molecule acts as an immunomodulator and induces antiviral activity
against rabies [51].
15. Scabies and other ectoparasites
Scabies (along with other ectoparasites) is one of the newest members to join the NTD
family along with chromoblastomycosis and other deep mycoses, and snakebite envenoming. In
2017, scabies was identified by the WHO as a neglected tropical disease [52]. Human scabies is
highly contagious, and it is caused by the parasite Sarcoptes scabiei var hominis (itch mite).
Scabies is caused by the infestation of the tiny mites in the exterior layers of the skin. Scabies
infestation may become more problematic by a secondary bacterial infection that could result in
septicemia, post-streptococcal glomerulonephritis like renal disease and rheumatic cardiac
disease. Scabies has very recently been included in the list of NTDs; systematic data is not
currently available. The current treatment of scabies includes oral administration of the
heterocyclic macrolide ivermectin (Figure 1) in the case of pre-bacterial infection (primary
management). To treat post-bacterial infection (secondary management) several heterocyclic
antibiotics/antiseptics are prescribed [52,53].
16. Schistosomiasis
Schistosomiasis is the next disease to be considered. The disease is caused by parasitic
blood flukes belonging to the genus Schistosoma. In 2017 only, 220.8 million individuals were
infected and needed preventive treatment, but only 102.3 individuals were treated. In 2016, a
staggering 53.7% remained untreated. The larval form of the parasite is harbored by snails.
These snails live in freshwater and are responsible for the subsequent release of the larval
parasites into water sources. These larvae then infiltrate the skin of a human and undergo
maturation. The mature worms reside in the circulatory system and eggs are released. The eggs
are either incorporated into tissues producing symptoms or excreted from the body, allowing

contamination of further sources to occur. The eggs give rise to larvae in the water allowing for
the cycle of infestation to begin anew. However, there are different forms of the disease caused
by unique species of worm. Schistosoma haematobium, Schistosoma mansoni, Schistosoma
japonicum, Schistosoma mekongi, Schistosoma guineensis (and the similar Schistosoma
intercalatum) are all implicated in producing the symptoms characteristic of intestinal
schistosomiasis. However, Schistosoma haematobium is implicated in urogenital
schistosomiasis. Symptoms produced in the intestinal form include discomfort, diarrhea, blood in
the feces, and enlargement of organs including the liver and spleen. Abdominal blood pressure
may also be elevated. Urogenital schistosomiasis is characterized by blood in urine, tissue
damage including fibrosis, and kidney failure in later stages. Cancer of the bladder, hepatic
failure, as well as male and female-specific urogenital issues may result, resulting in ectopic
pregnancies and loss of fertility in certain cases.
Regarding treatment, a heterocyclic pyrazinoisoquinolinone derivative, praziquantel
(Figure 1) is a highly effective drug against all the parasitic worm species that cause the disease.
This heterocyclic drug is inexpensive, has minimal side effects and is clinically effective in
reducing symptoms of the disease [54,55]. Previously discussed amino alcohol heterocyclic
compounds that could be useful in treating echinococcosis may also be useful in treating
schistosomiasis [19]. Interestingly, in a new study, it was reported that heterocyclic oxazine
derivatives demonstrated ex vivo efficacy against the specific parasite Schistosoma mansoni. The
molecules had a low cytotoxic effect in normal cell lines, indicating that the heterocycles are
specific towards targeting disease-causing organisms. A considerable benefit would be granted
by the development of this drug as a backup to oral praziquantel. The mechanism of action of the
oxazine derivatives is the destruction of the outer layer that encapsulates adult worms [56].
17. Soil-transmitted helminthiases
Soil-transmitted helminthiases are certain types of infections that are caused by multiple
organisms, commonly known as intestinal worms. The particular species areAscaris
lumbricoides, Trichuris trichiura, Necator americanus and Ancylostoma duodenale. This disease
currently affects 1.5 billion people worldwide. This is almost a quarter of the world’s population!
The disease derives its name from that method of transmission of the eggs of the worms from the
fecal excretions of infected individuals into open-air/soil. The eggs are produced by worms

residing in the intestine of an infected individual. Interestingly, because the worms do not
replicate in the host, reinfection is the primary factor that allows the disease to continue to persist
in individuals. Fresh fecal matter containing eggs is not infective; eggs do not immediately
mature in the soil. The eggs generally take 2 to 3 weeks to mature. However, once maturation
does occur, Necator americanus and Ancylostoma duodenale eggs do not just merely become
infective by simple ingestion as with the other species, but rather hatch and produce larvae which
can infect humans through direct skin contact. The primary methods of ingestion of the other
species’ eggs include the consumption of contaminated food and water that contains the
organisms. Depending on the concentration of worms in the body, a person may be
asymptomatic or express stunted growth, anemic symptoms, loose stools, discomfort, weakness,
and severe nutrient loss because the helminths feed on host blood and tissues [57,58].
The primary strategy of controlling morbidity due to soil-transmitted helminths should
include proper sanitation, hygiene, and availability of clean drinking water. Treatment includes
administration of the two heterocyclic benzimidazole drugs mebendazole and albendazole, given
in 500 mg and 400 mg dosages, respectively. These treatments have been previously shown to be
effective against lymphatic filariasis (solely, albendazole) and echinococcosis and have a good
safety record. Both drugs are low-cost and can be orally administered quite easily [57,58].
Recently, thiazolid-4-one containing substituted chloro-quinoline derivatives have shown highly
promising results for the treatment of this disease [59]. In addition, a novel series of Schiff base
derivatives of 1,8 naphthyridine (a heterocyclic compound) demonstrated significant
anthelmintic activity. This study was assessed using albendazole as control and measuring the
time of paralysis for the species Perionyx excavatus and Pheritima posthuma [60]. These
heterocyclic molecules have shown present effectiveness and future promise against soiltransmitted helminthiasis.
18. Snakebite envenoming
Snakebite is considered as a neglected health issue in many countries. As a result, reliable
data is not available. However, according to the WHO estimation, approximately 5.4 million
people experience snakebites each year and about half of that number (2.7 million) face
envenoming. Currently, there is no heterocyclic drug for the treatment of snakebite envenoming;
antivenom immunoglobulins are used to reverse or inhibit snakebite envenoming. Snakebite

envenoming has been included only for the thoroughness of the discussion. It is estimated that
snakebite envenoming is responsible for about 81,000 to 138,000 deaths each year. Severe
effects include respiratory failure, hemorrhage, paralysis, kidney function failure and limb injury
that could result in amputation. Statistics on snakebites and envenomation including death and
disability counts are presented briefly in Figure 11. Because of their smaller body mass, the
children face greater symptomatic consequences than adults. Immunoglobulin treatment is
effective, but it is not always easily available because of insufficient production, marketing, and
distribution issues. As this disease is concentrated in the rural areas of less developed countries,
it is often prohibitively expensive to gather data and to arrange for the production of quality
antivenoms for affected individuals [61].
<Figure 11>
Although there is no heterocyclic antivenom molecule available to date, a series of
potential heterocyclic molecules have been patented that could be used for treating the skin
lesions and related damages that occur as a result of envenomation. These compounds consist of
imidazoquinoline amines, imidazopyridine amines, 6/7-fused cycloalkylimidazopyridine amines,
imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, oxazolopyridine amines,
oxazoloquinoline amines, thiazolopyridine amines, thiazoloquinoline amines, and 1,2-bridged
imidazoquinoline amines. These compounds would work by direct application to the site of
envenomation and may help reduce the physical damage that envenomation causes [62].
19. Taeniasis/Cysticercosis
Taeniasis is a neglected tropical disease (a parasitic infection) that is caused by three
different species of tapeworm. The pork tapeworm (Taenia solium), the beef tapeworm (Taenia
saginata), and the Asian tapeworm (Taenia asiatica) are the individual species responsible for
the pathology. The infection by the beef tapeworm may occur through the consumption of
contaminated beef tissue and infection by Taenia asiatica may occur through the consumption of
contaminated pig liver. The ingestion of these meats results in the residence of the adult
tapeworm in the human intestine. This is known as Taeniasis. This infection does not result in
significant clinical symptomology. Taeniasis symptoms caused by any of the three adult worm
species are relatively mild and generally include abdominal discomfort, loose stools, pain, and
constipation. These effects generally occur after maturation of the adult worms, which generally

takes 8 weeks. The effects will continue until treatment is administered or until the tapeworm
dies (after a period of up to 2-3 years for the Taenia solium species). However, the species that
causes a significant health problem globally is Taenia solium. This is because infection with this
tapeworm after initially causing taeniasis may also cause cysticercosis [63]. Cysticercosis is
much more devastating than taeniasis, as cysticercosis patients not only host tapeworms in their
intestines but also host larvae (cysticerci) of the tapeworm in different body parts like the
muscle, epidermis, eyes and perhaps most devastating, the central nervous system (CNS). The
symptoms of cysticercosis include epileptic seizures, severe pain, convulsions and visual
impairment [64]. The disease may result in fatality. The total number of people suffering
specifically from this disease also termed neurocysticercosis, ranges from 2.56-8.30 million
people. To make matters more difficult, for cysticercosis, the larval development period may
vary on a case by case basis and symptoms may not appear for years. The impact of
taeniasis/cysticercosis has been summarized in Figure 12.
<Figure 12>
Treatment of taeniasis, caused by adult worms, includes the singular, oral administration
of a heterocyclic (pyrazino[2,1-a]isoquinolin-4-one) derivative, praziquantel, (Figure 1) in a
dosage of 5-10 mg/kg of the body weight. Praziquantel acts as an effective deworming agent for
taeniasis patients. In some cases, a non-heterocyclic drug (niclosamide) is also prescribed.
Treatment of cysticercosis is more complex and patient-specific. Prolonged treatment with a
combination of drugs is required. Praziquantel alone or in combination with albendazole is
recommended. Both drugs are heterocyclic (Figure 1). The physical removal of cysts may induce
an inflammatory response from the body, and corticosteroids may be administered to reduce the
pain. Additionally, it is not uncommon for antiepileptic drugs to be administered in conjunction
with the corticosteroids or independently in order to prevent seizures. Surgery may also be
required. Interestingly, the regulation of a heterocyclic drug (oxfendazole) in pigs is of key
importance. Oxfendazole, a benzimidazole anthelmintic agent (Figure 1) at a dose concentration
of 30 mg/kg of the bodyweight is recommended as an anthelmintic drug for pigs and can prevent
the transmission of the Taenia solium species [65,66]. Perhaps the most interesting heterocyclic
development for this class of diseases is that of the guanidine containing heterocyclic compounds
discussed previously. Because the compounds seem to have significant side-effects, appropriate

development of these heterocyclic compounds might be beneficial for the treatment of a wide
array of patients. In addition, treatment may be simplified by the administration of such drugs in
the case of multiple infection/infestation [18]. Moreover, N-oxide heterocyclic molecules may be
potent against a wide array of neglected tropical diseases as previously discussed [32].
20. Trachoma
Trachoma is the leading cause of blindness worldwide due to a single parasitic infection,
and it is responsible for vision loss in 1.9 million people. The blindness caused by this disease is
irreparable. The disease is caused by a bacterium termed Chlamydia trachomatis and is
considered a hygiene-related disease. The mode of infection is through direct physical contact,
the sharing of clothes/towels used to wipe eyes, and the encounter of nasal discharge of infected
individuals. The disease can also be transmitted by flies that incorporate the bacterium through
direct contact with either an infected eye or nasal discharge of the patient. Symptoms include
progressive visual impairment as a result of the scarring of the inner eyelid; this is perpetuated by
multiple infections. This scarring physically changes the conformation of the eyelid so that it
turns in on itself. This allows abrasive rubbing of the eyelashes against the eye. Once this occurs,
further degradation of the eyeball/cornea will result in blindness [67,68].
<Figure 13>
The WHO has introduced SAFE [S stands for surgery if the disease is at an advanced
stage, A stands for antibiotics to reduce/remove the bacterial infection, F stands for facial
cleanliness, E indicates environmental protection to remove the bacterium] as a strategy to
combat trachoma. As a part of antibiotic administration, the azaheterocyclic macrolide
azithromycin (Figure 1) is widely used. In 2017, about 83.5 million trachoma patients were
treated with azithromycin. [68]. Recently patented 2-amino-N-(heteroarylsulfinyl)-acetamide
derivatives could demonstrate potent antibacterial activity against a wide array of bacteria,
including Chlamydia trachomatis. The mechanism of action is the inhibition of the bacterial
aminoacyl-tRNA synthetase. Therefore, the bacterial cell is unable to proliferate, and the
disease-causing process is ceased [69]. In another patent, N-[3-[[4-(2-pyridyl)pyrimidin-2-yl]
amino]phenyl]-4-[(piperazin-1-yl)methyl]benzamide derivatives were demonstrated to be
effective antitrachomacidal agents for the treatment of trachoma [70]. The mechanism of action
includes the inhibition of protein kinases in Chlamydia trachomatis that are highly associated

with trachoma. In particular, these heterocyclic compounds are effective inhibitors of Abelson
protein kinases including, but not limited to, c-Abl1, c-Abl2, and c-kit [70]. These developments
may lead to an excellent selective drug that can be used in treating trachoma. Mass
antibiotic/drug administration will not result in the elimination of trachoma; for this purpose,
health and environmental hygiene must also be seriously considered [71].
21. Yaws (Endemic treponematoses)
Yaws is a chronic bacterial infection, and the majority of victims are children in the age
group ranging from 6-10: in some cases, up to age 15. Yaws is prevalent in the tropical jungle
areas where the weather is relatively warm and humid. It is caused by the bacterium Treponema
pallidum, which belongs to the subspecies pertenue. Infection is caused by direct skin contact as
a result of minor injuries. The period of incubation can range from 9-90 days, with the mean
value being 3 weeks. Yaws affects the skin, bone and cartilaginous tissues. It has been estimated
that 89 million people live in areas endemic to Yaws. Yaws results in the production of a
papilloma that is saturated with bacteria. This papilloma subsequently converts into an ulcer. The
ulcer formation results in the highly contagious transfer of the disease by abrasions (in the
absence of treatment). Secondary effects of yaws can include dactylitis, the formation of yellow
raised areas and discomfort. Yaws infection may lead to another subtype called ‘bejel’, or
endemic syphilis as well as pinta [72]. Figure 14 summarizes the current status of yaws
worldwide [73].
<Figure 14>
The treatment of yaws involves the use of either of two heterocyclic antibiotics (Figure
1): azithromycin (oral administration) or benzathine penicillin (intramuscular administration).
Interestingly, the benzathine penicillin injection was the only remedy for Yaws for more than 60
years, whereas the inclusion of oral azithromycin treatment is comparatively recent (2012). The
dosage of azithromycin administered is 30 mg/kg of the body weight and must not exceed 2g in
total. Benzathine penicillin injection can alternatively be used, although it is currently less
convenient after the discovery of the high therapeutic efficacy of oral azithromycin. Currently,
benzathine penicillin injection is primarily used as a backup treatment for those who do not
respond well to azithromycin. The dosage is administered intramuscularly, at a concentration of
0.6 million units for those under the age of 10 and a concentration of 1.2 million units for those

aged 10 years or older. Both treatments are extremely effective and cure 95% of patients [73]. In
2011, patented heterocyclic tetrazolone derivatives were found to be potentially effective in
curing antimicrobial diseases such as Yaws. Additionally, triazole derivatives were found to have
a similar effect. Both series of compounds are implicated in the inhibition of the protein fatty
acid synthase required for microbial sustenance and proliferation in Yaws [74,75].
22. CONCLUSION
Although the WHO has taken preventive and curative measures the past few decades, many
NTDs are still literally ‘neglected’. The large incidence of mortality, morbidity, and disability
attributed each year due to NTDs is magnitudes higher than that of diseases like cancer, diabetes,
HIV/AIDS, cardiovascular diseases, or central nervous system-related diseases that receive the
majority of attention in developed countries. The WHO, along with several sister organizations,
is continuing the effort to update and revise the data pertaining to those suffering from various
NTDs worldwide. Unfortunately, a few known and/or unknown tropical diseases (for example,
encephalitis, ringworm, etc.) are not yet included in the NTD list. In many parts of the world, in
particular Africa and some parts of Asia and Latin America, there are no standard diagnostic
procedures and health professionals do not have sufficient training to isolate a causative agent of
a disease. The use of vague diagnoses such as ‘viral fever’ does not assist in the process of
treatment. To overcome this problem, the governments, international health organizations, and
WHO should work together to allocate funding and resources to institute a higher standard of
care. Diseases do not pay attention to nationality, color, race, religion, origin or ethnicity, and the
poor communities of the world are often the main sufferers of NTDs. All humans deserve proper
treatment. This review indicates that most of the drugs that are currently being used for the
treatment of various NTDs are heterocyclic in nature. Because of their unique character,
heteroatom-containing compounds are capable of forming additional drug-protein interactions
like hydrogen bonding, co-ordination, salt-bridge formation, etc. with diverse protein molecules.
It is well known that different diseases are related to the upregulation or downregulation of
various proteins, and additional protein-ligand interactions are crucial in imparting therapeutic
activity by protein regulation. Heterocyclic molecules are implicated in the treatment of a
plethora of NTDs, and it makes scientific sense to continue to exploit the therapeutic effects of
diverse heterocyclic scaffolds. Because neglected tropical diseases often involve vast proportions

of the world’s most vulnerable populations, easily administrable, stable and economical
heterocyclic drugs are desperately needed. As NTDs mainly affect impoverished people, brutal
reality is that most pharmaceutical companies are not interested in developing effective drugs for
NTDs. Although the number afflicted is extremely large, the profit margin is small;
disadvantaged people cannot afford medication. Unfortunately, research in this area is not greatly
encouraged and consequently there is lack of funding. This pessimistic outlook must be changed,
and resources must be put forth to address these diseases. Many of the NTDs are directly related
to the poverty, hygiene, environment, nutrition, and lifestyle of the patients. As stated earlier,
lacking of research funds and interest might be the two major reasons why detailed mechanisms
of actions of most the drugs are still unknown. At the same time, although there is no direct way
to control warm and humid weather which is one of the influencing factors for some of these
diseases, but non-medical measures like emphasis on personal hygiene, appropriate sanitation,
clean drinking water, vaccination, and nutrition should also be encouraged by the
local/state/national government to combat NTDs. The treatment of NTDs requires a concerted
approach that is as unique as all the people suffering from them. Global approaches to public
welfare have worked wonders and eliminated endemic diseases in the past; there is no reason
that the same cannot be achieved for NTDs.
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